DRD2 and major depressive disorder: Drug–gene interaction studies highlight antipsychotics, estrogen-related drugs, DRD2-targeting drugs, calcium channel modulators, and serotonin receptor antagonism as potential drugs to counteract transcriptional effects of depression risk [3, 162].